# Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

> **NCT02939014** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 39 (actual)

## Conditions studied

- Hodgkin Disease
- Lymphoma, Large-Cell, Anaplastic

## Interventions

- **DRUG:** Brentuximab Vedotin

## Key facts

- **NCT ID:** NCT02939014
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-07
- **Primary completion:** 2018-08-02
- **Final completion:** 2020-02-03
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02939014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02939014, "Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02939014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*